CONTENTS:
- Building partnerships between law enforcement and harm reduction programs [Editorial]. Jardine M., p. 377-378.
- The contractual governance of drug users in treatment [Commentary]. Bacon M., Seddon T., p. 379-384.
- 'Silk Road', the virtual drug marketplace: A single case study of user experiences. Hout M.C.V., Bingham T., p. 385-391.
- 'You've got m@il: Fluoxetine coming soon!': Accessibility and quality of a prescription drug sold on the web. Gelatti U., Pedrazzani R., Marcantoni C., Mascaretti S., Repice C., Filippucci L., et al., p. 392-401.
- The OxyContin crisis: Problematisation and responsibilisation strategies in addiction, pain, and general medicine journals. Whelan E., Asbridge M., p. 402-411.
- The impact of New Zealand's 2008 prohibition of piperazine-based party pills on young people's substance use: Results of a longitudinal, web-based study. Sheridan J., Dong C.Y., Butler R., Barnes J., p. 412-422.
- Injecting behaviour and service use among young injectors in Albania, Moldova, Romania and Serbia. Busza J., Douthwaite M., Bani R., Scutelniciuc O., Preda M., Simic D., p. 423-431.
- Key drug use, health and socio-economic characteristics of young crack users in two Brazilian cities. Santos Cruz M., Andrade T., Bastos F.I., Leal E., Bertoni N., Villar L.M., et al., p. 432-438.
- Patterns of excess alcohol consumption among school children in two English comprehensive schools. Armitage C.J., p. 439-444.
- The role of child protection in cannabis grow-operations. Douglas J., Sullivan R., p. 445-448.
- The Cedar Project: Impacts of policing among young Aboriginal people who use injection and non-injection drugs in British Columbia, Canada. Pan S.W., Christian C.W.M., Pearce M.E., Blair A.H., Jongbloed K., Zhang H., et al., p. 449-459.
- Opiate substitution treatment to reduce in-prison drug injection: A natural experiment. Kinner S.A., Moore E., Spittal M.J., Indig D., p. 460-463.
- An ambiguous monolith - The Swedish drug issue as a political battleground 1965-1981. Edman J., p. 464-470.
- Structural factors that promote stigmatization of drug users with hepatitis C in hospital emergency departments. Paterson B., Hirsch G., Andres K., p. 471-478.
- Injection drug users’ involvement in drug dealing in the downtown eastside of Vancouver: Social organization and systemic violence. Small W., Maher L., Lawlor J., Wood E., Shannon K., Kerr T., p. 479-487.
- Patterns of alcohol, tobacco and cannabis use and related harm in city, regional and remote areas of Australia. Roxburgh A., Miller P., Dunn M., p. 488-491.
- First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland. Uosukainen H., Bell J.S., Laitinen K., Tacke U., Ilomäki J., Turunen J.H.O., p. 492-497.
- Harms caused by China's 1906-17 opium suppression intervention. Windle J., p. 498-505.
- The doping myth: 100 m sprint results are not improved by doping. Brown T.D., p. 506-507.
- Keeping the focus on safer practices: A Safer Practices Lens [Viewpoint]. McWilliam S., Jackson L.A., Dykeman M., Gahagan J., Karabanow J., p. 508-509.